In CRC, pDCs expressed IRF7 and were located close to CD8+ T cells, suggesting that they may enhance anti-tumor immunity through secretion of type I IFN and stimulation of CD8+ T cells.180 Interestingly, IRF7+ pDCs preferentially reside around CD4+ T cells during TLS development. The gene discussed is IRF7; the disease is neoplasm.